Life science companies like Emergent BioSolutions are feeling the pressure. We have had historically low venture capital activity and minimal initial public offerings over the past two years, and many are running out of cash. According to Audit Analytics’ data, 325 or 36% of public life sciences companies have received a going concern opinion on their 2023 financial statements. This indicates that there is substantial doubt about the company’s ability to meet its obligations as they become due within one year from the date of the financial statements. We have not seen a rate this high since 2012, when it was at 38%.    

In this article, Audit Analytics further examines Emergent BioSolutions, COVID-19 vaccine struggles, management shakeup and the fight for shareholder value.